When compared to TNFα inhibitors, tofacitinib failed to meet noninferiority criteria for both incidence of cancers and MACE (103).The study determined that there is indeed a difference in adverse events experienced between users of tofacitinib and TNFα inhibitors. The gene discussed is TNF; the disease is cancer.